Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation, 51439-51440 [2017-24090]
Download as PDF
<![CDATA[
51439
Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices
Pmangrum on DSK3GDR082PROD with NOTICES
Registrant, both with respect to the
volume of drugs being diverted and by
denying that he was engaged in
diverting and abusing the controlled
substances. As explained above,
Registrant’s and Chapman’s misconduct
in diverting drugs, which the latter
personally abused, was actionable
misconduct under both Factor Four
(compliance with applicable laws
related to controlled substances) and
Factor Five (other conduct which may
threaten public health and safety). As
the DI explained, had Chapman been
candid during the June 30, 2016
interview, he and his colleagues ‘‘would
have pursued immediate criminal action
against Chapman’’ as well as
administrative action against Registrant.
Indeed, Chapman’s subsequent
admissions during the July 22, 2016
interview supported both criminal
charges against Chapman and the
Immediate Suspension Order.
Accordingly, I conclude that the
evidence with respect to Factor Five
establishes that Registrant’s principal
was abusing controlled substances and
that he made several materially false
statements to DEA investigators. I also
conclude that these acts constitute
actionable misconduct which may
threaten public health and safety.
Summary of Factors Four and Five and
Imminent Danger
As found above, the Government’s
evidence establishes that Registrant
unlawfully distributed controlled
substances to Chapman and failed to
maintain required records. The evidence
also establishes that Registrant’s
principal and pharmacist in charge
unlawfully possessed controlled
substances, destroyed records that
Registrant was required to maintain,
abused controlled substances and made
materially false statements to DEA
Investigators. I therefore find that
Registrant has committed such acts as to
render its registration inconsistent with
the public interest. 21 U.S.C. 824(a)(4).
For purposes of the imminent danger
inquiry, these findings also support the
conclusion that Registrant has ‘‘fail[ed]
. . . to maintain effective controls
against diversion or otherwise comply
with the obligations of a registrant
under’’ the CSA. 21 U.S.C. 824(d)(2).
Also, the evidence that Chapman was
diverting 200 to 300 milligrams of
narcotics per day, which he then abused
(along with the evidence showing that
he was hospitalized for an overdose on
multiple occasions), establishes that
there was ‘‘a substantial likelihood of an
immediate threat that death, serious
bodily harm, or abuse of a controlled
substance [would] occur in the absence
of the immediate suspension of
[Registrant’] registration.’’ Id. I therefor
affirm the issuance of the Immediate
Suspension Order.
Pursuant to 21 U.S.C. 824(f), ‘‘[u]pon
a revocation order becoming final, all
. . . controlled substances’’ seized
pursuant to a suspension order ‘‘shall be
forfeited to the United States’’ and ‘‘[a]ll
right, title, and interest in such
controlled substances shall vest in the
United States upon a revocation order
becoming final.’’ As the Agency has
previously held, a registrant cannot
defeat the effect of this provision by
allowing its registration to expire.’’
S & S Pharmacy, Inc., d/b/a Platinum
Pharmacy & Compounding, 78 FR
57656, 57659 (2013) (citing
Meetinghouse Community Pharmacy,
Inc., 74 FR 10073, 10074 n.5 (2009); RX
Direct Pharmacy, Inc., 72 FR 54070,
54072 n.4 (2007)). Registrant had the
right to challenge the Immediate
Suspension Order before the Agency but
chose not to. And had Registrant not
allowed its registration to expire, I
would have revoked it.
Accordingly, I will order that the
controlled substances seized pursuant to
the Immediate Suspension Order be
forfeited to the United States. 21 U.S.C.
824(f). I will also declare that ‘‘[a]ll,
right, title, and interest in’’ the
controlled substances that were seized
pursuant to the Suspension Order have
vested in the United States. Id.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 824(a) and (d), as well as
28 CFR 0.100(b), I order that the Order
of Immediate Suspension issued to Chip
RX d/b/a City Center Pharmacy be, and
it hereby is, affirmed. Pursuant to the
authority vested in me by 21 U.S.C.
824(f), I order that all controlled
substances seized pursuant to the Order
of Immediate Suspension be, and they
hereby are, forfeited to the United
States. Pursuant to the authority vested
in me by 21 U.S.C. 824(f), I also declare
that all right, title, and interest in all
controlled substances seized pursuant to
the Order of Immediate Suspension be,
and they hereby are, vested in the
United States. This Order is applicable
December 6, 2017.
Dated: October 31, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017–24093 Filed 11–3–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Cerilliant
Corporation
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 5, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on May 23,
2017, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock,
Texas 78665–2402 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-)4-fluorobenzyl)-1-H-indazole-3-carboxamide) ............
MDMB-FUBINACA (Methyl-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .......................
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) .........
VerDate Sep<11>2014
14:48 Nov 03, 2017
Jkt 244001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\06NON1.SGM
06NON1
7010
7020
7032
Schedule
I
I
I
51440
Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices
Controlled substance
Drug code
5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1-1H-indazole-3-carboxamido)-3-methylbutanoate) ............................................
5F-ADB;5F-MDMB-PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .........
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-(cyclohenxylmethyl)-1H-indole-3-carboxamido)-3,3dimethylbutanoate).
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1-1H-indazole-3-carboxamide) .................................
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) ...............................................................
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) .................................................................................
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) .........................................
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) .............................................................
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to its
customers.
Dated: October 27, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–24090 Filed 11–3–17; 8:45 am]
BILLING CODE 4410–09–P
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Notice: (16–083)]
Centennial Challenges: 3D-Printed
Habitat Challenge
National Aeronautics and
Space Administration (NASA).
ACTION: Notice of Centennial Challenges
3D-Printed Habitat Challenge Phase 3:
On-Site Habitat Competition.
AGENCY:
The 3D-Printed Habitat
(3DPH) Challenge Phase 3 On-Site
Habitat Competition is open, and teams
that wish to compete may now register.
Centennial Challenges is a program of
prize competitions to stimulate
innovation in technologies of interest
and value to NASA and the nation. The
3DPH Challenge Phase 3 On-Site Habitat
Competition is a prize competition with
a $2,000,000 total prize purse to develop
and demonstrate capabilities to
autonomously manufacture through 3Dprinting technologies a habitat on
another planetary body using mission
recycled materials and/or local
indigenous materials. The Phase 3
competition consists of 5 levels. This
technology demonstration competition
has great potential value for terrestrial
applications.
Pmangrum on DSK3GDR082PROD with NOTICES
SUMMARY:
Challenge registration opens
November 7, 2017, and will remain
open until February 15, 2018. Early and
Late registrations are available with
discount or late fee respectively.
Competitors will be allowed the option
to participate in the Virtual
Construction competitions levels 1 & 4
only with a reduced registration fee.
DATES:
VerDate Sep<11>2014
14:48 Nov 03, 2017
Jkt 244001
Other important dates:
May 16, 2018 Level 1: Virtual
Construction Building Information
Modeling (BIM)—60% Design Results
due to Judges
July 11, 2018 Level 2: Foundation Test
Results due to Judges
December 5, 2018 Level 3: Hydrostatic
Test Results due to Judges
January 16, 2019 Level 4: Virtual
Construction BIM—100% Design
Results due to Judges
April 29—May 4, 2019 Level 5: Subscale
Habitat Competition
ADDRESSES: The Level 5 On-Site
Subscale Habitat Head-to-Head
challenge competition will take place at:
Caterpillar Edwards Demonstration and
Learning Center, 5801 N. Smith Rd.,
Edwards, IL 61528.
FOR FURTHER INFORMATION CONTACT: To
register for or get additional information
regarding the 3D Printed Habitat
Challenge, please visit: https://
bradley.edu/challenge For general
information on the NASA Centennial
Challenges Program please visit: https://
www.nasa.gov/challenges. General
questions and comments regarding the
program should be addressed to Monsi
Roman, Centennial Challenges Program,
NASA Marshall Space Flight Center
Huntsville, AL 35812. Email address:
hq-stmd-centennialchallenges@
mail.nasa.gov.
SUPPLEMENTARY INFORMATION:
Summary
The 3DPH Challenge Phase 3
Competition (On-Site Habitat) follows
earlier phases of the Challenge as
described below.
• Design Competition (Phase 1)—
focused on developing innovative
habitat architectural concepts that take
advantage of the unique capabilities that
3D-Printing offers (completed in 2015).
• Structural Member Competition
(Phase 2)—focused on the core 3DPrinting fabrication technologies and
materials properties needed to
manufacture structural components
from indigenous materials combined
with recyclables, or indigenous
materials alone (completed in 2017).
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Schedule
7033
7034
7042
I
I
I
7049
9547
9811
9824
9834
I
I
I
I
I
The current competition, Phase 3 (OnSite Habitat), will focus on the
technology for autonomous 3D-printing
and construction of a complete 1:3 subscale habitat (∼10 m2). This competition
will involve elements from Phase 1
design and Phase 2 materials to
demonstrate the technology for
autonomous construction needed for
building a habitat on another planet or
even on remote locations on Earth.
A Phase 4 competition (Full-Scale
Habitat), calling for the development of
an autonomous 3D-printed construction
of a full-scale habitat (∼93 m2), is
planned to be announced at a later date.
I. Prize Amounts
The 3D Printed Habitat Challenge
Phase 3 On-Site Habitat Competition
purse is $2,000,000 (two million dollars)
to be disbursed as follows:
Level 1: Virtual Construction BIM—60%
Design
$100,000 total prize money to be
awarded to top 5 qualifiers based on
scoring, as articulated in the
competition rules.
Level 2: Foundation Test
$400,000 total prize money to be
awarded to top 10 qualifiers based on
scoring, as articulated in the
competition rules.
Level 3: Hydrostatic Test
$600,000 total prize money to be
awarded to top 8 qualifiers based on
scoring, as articulated in the
competition rules.
Level 4: Virtual Construction BIM—
100% Design
$100,000 total prize money to be
awarded to top 3 qualifiers based on
scoring, as articulated in the
competition rules.
Level 5: Subscale Habitat Competition
$500,000 to first place
$200,000 to second place
$100,000 to third place
These awards will be made based on
scoring, as articulated in the
competition rules.
E:\FR\FM\06NON1.SGM
06NON1
]]>Agencies
[Federal Register Volume 82, Number 213 (Monday, November 6, 2017)]
[Notices]
[Pages 51439-51440]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24090]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application:
Cerilliant Corporation
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before January 5, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on May
23, 2017, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round
Rock, Texas 78665-2402 applied to be registered as a bulk manufacturer
of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1- 7010 I
oxobutan-2-yl)-1-)4-fluorobenzyl)-1-H-
indazole-3-carboxamide).
MDMB-FUBINACA (Methyl-2-(1-(4- 7020 I
fluorobenzyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate).
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1- 7032 I
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide).
[[Page 51440]]
5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1-1H- 7033 I
indazole-3-carboxamido)-3-
methylbutanoate).
5F-ADB;5F-MDMB-PINACA (Methyl 2-(1-(5- 7034 I
fluoropentyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate).
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1- 7042 I
(cyclohenxylmethyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate).
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)- 7049 I
1-(5-fluoropentyl)-1-1H-indazole-3-
carboxamide).
U-47700 (3,4-dichloro-N-[2- 9547 I
(dimethylamino)cyclohexyl]-N-
methylbenzamide).
Acryl fentanyl (N-(1-phenethylpiperidin-4- 9811 I
yl)-N-phenylacrylamide).
4-Fluoroisobutyryl fentanyl (N-(4- 9824 I
fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)isobutyramide).
Furanyl fentanyl (N-(1-phenethylpiperidin- 9834 I
4-yl)-N-phenylfuran-2-carboxamide).
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances to make reference standards which will be
distributed to its customers.
Dated: October 27, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-24090 Filed 11-3-17; 8:45 am]
BILLING CODE 4410-09-P
